ECSP045493A - Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a - Google Patents

Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a

Info

Publication number
ECSP045493A
ECSP045493A EC2004005493A ECSP045493A ECSP045493A EC SP045493 A ECSP045493 A EC SP045493A EC 2004005493 A EC2004005493 A EC 2004005493A EC SP045493 A ECSP045493 A EC SP045493A EC SP045493 A ECSP045493 A EC SP045493A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
compositions containing
polymorph
flibanserine
new pharmaceutical
Prior art date
Application number
EC2004005493A
Other languages
English (en)
Inventor
Thomas Friedl
Guido Bernhard Edmund Radtke
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP045493A publication Critical patent/ECSP045493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención se refiere a composiciones farmacéuticas orales que contienen flibanserina, métodos para su preparación y su uso como medicamento.
EC2004005493A 2002-05-22 2004-12-13 Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a ECSP045493A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22

Publications (1)

Publication Number Publication Date
ECSP045493A true ECSP045493A (es) 2005-03-10

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005493A ECSP045493A (es) 2002-05-22 2004-12-13 Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a

Country Status (25)

Country Link
EP (1) EP1511489B1 (es)
JP (1) JP3919788B2 (es)
KR (1) KR101054237B1 (es)
CN (3) CN1655789A (es)
AT (1) ATE499939T1 (es)
BR (1) BRPI0311189B8 (es)
CA (1) CA2483597C (es)
CY (1) CY1111470T1 (es)
DE (1) DE60336225D1 (es)
DK (1) DK1511489T3 (es)
EA (1) EA007185B1 (es)
EC (1) ECSP045493A (es)
ES (1) ES2361994T3 (es)
HR (1) HRP20041092B1 (es)
IL (1) IL164440A0 (es)
ME (1) MEP55308A (es)
MX (1) MXPA04011487A (es)
NO (1) NO329414B1 (es)
NZ (1) NZ537253A (es)
PL (1) PL211062B1 (es)
RS (1) RS51718B (es)
SI (1) SI1511489T1 (es)
UA (1) UA80135C2 (es)
WO (1) WO2003097058A1 (es)
ZA (1) ZA200408151B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
MX2009001551A (es) 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
CA2672957C (en) 2006-12-20 2015-04-14 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
CN113683570A (zh) * 2016-01-31 2021-11-23 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
WO2003014079A1 (en) * 2001-08-02 2003-02-20 Bidachem S.P.A Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
DE60336225D1 (de) 2011-04-14
CN101002780A (zh) 2007-07-25
NZ537253A (en) 2007-09-28
BRPI0311189B1 (pt) 2019-04-09
ATE499939T1 (de) 2011-03-15
BRPI0311189B8 (pt) 2021-05-25
EA200401515A1 (ru) 2005-06-30
NO329414B1 (no) 2010-10-18
RS51718B (en) 2011-10-31
PL372457A1 (en) 2005-07-25
WO2003097058A1 (en) 2003-11-27
HRP20041092A2 (en) 2005-06-30
AU2003240672A1 (en) 2003-12-02
EP1511489B1 (en) 2011-03-02
RS98704A (en) 2006-12-15
SI1511489T1 (sl) 2011-06-30
PL211062B1 (pl) 2012-04-30
IL164440A0 (en) 2005-12-18
CA2483597C (en) 2010-02-09
ES2361994T3 (es) 2011-06-27
CN1655789A (zh) 2005-08-17
BR0311189A (pt) 2005-02-22
DK1511489T3 (da) 2011-05-02
HRP20041092B1 (hr) 2013-05-31
NO20044547L (no) 2004-12-17
MEP55308A (en) 2011-05-10
KR20040111668A (ko) 2004-12-31
EA007185B1 (ru) 2006-08-25
EP1511489A1 (en) 2005-03-09
UA80135C2 (en) 2007-08-27
MXPA04011487A (es) 2005-02-14
JP3919788B2 (ja) 2007-05-30
JP2005530787A (ja) 2005-10-13
ZA200408151B (en) 2006-06-28
CN102240289A (zh) 2011-11-16
KR101054237B1 (ko) 2011-08-08
CA2483597A1 (en) 2003-11-27
CY1111470T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
NO20064808L (no) Orale matrixformuleringer med licarbazepin
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
NO20064783L (no) Opplosningstabeletter med licarbazepin
ECSP066292A (es) Sistemas semi-sólidos que contienen derivados de azetidina
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.
IL162857A0 (en) Oral vaccination
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine